NCT04224155View on ClinicalTrials.gov

Clinical Study to Evaluate the Safety and Performance of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction

NACompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

June 14, 2022

Study Completion Date

June 14, 2022

Conditions
Cataract
Interventions
DEVICE

enVista MX60EFH trifocal intraocular lenses (IOLs)

enVista MX60EFH trifocal intraocular lenses (IOLs) implanted bilaterally

DEVICE

enVista MX60E monofocal intraocular lenses (IOLs)

enVista MX60E monofocal intraocular lenses (IOLs) implanted bilaterally

Trial Locations (9)

Unknown

Bausch Site 106, Calgary

Bausch Site 105, Toronto

Bausch Site 107, Toronto

Bausch Site 108, Vaughan

Bausch Site 113, Longueuil

Bausch Site 104, Montreal

L4K 2Z5

Bausch Site 102, Concord

L6H 0J8

Bausch Site 103, Mississauga

J7H 0E8

Bausch Site 101, Boisbriand

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT04224155 - Clinical Study to Evaluate the Safety and Performance of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction | Biotech Hunter | Biotech Hunter